Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
| | | |

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

On Jul. 10, 2025, Moderna announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental…

U.S.  Implements New Export Controls to Address National Security Risks Related to Biotechnology
| | | | | | | | | | | |

U.S. Implements New Export Controls to Address National Security Risks Related to Biotechnology

On Jan. 15, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) released an Interim…

Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
| | |

Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

On Sept. 13, 2024, CSL Seqirus and sa-mRNA pioneer Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor…